TAK-418

TAK-418 is a selective, orally active LSD1 (KDM1A) enzyme inhibitor with an IC50 of 2.9 nM. TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models[1][2].

Product Specifications

CAS Number

[1818252-53-7]

UNSPSC

12352005

Target

Histone Demethylase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/tak-418.html

Purity

99.81

Solubility

DMSO : 55 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : ≥ 16.67 mg/mL

Smiles

O=C(C1=CSC([C@H]2[C@H](NCC3CC3)C2)=C1)NC4CCOCC4.[H]Cl

Molecular Formula

C17H25ClN2O2S

Molecular Weight

356.91

References & Citations

[1]Baba R, et al. LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models. Sci Adv. 2021;7 (11) :eaba1187. Published 2021 Mar 12.|[2]Zhang L, et al. Inhibition of KDM1A activity restores adult neurogenesis and improves hippocampal memory in a mouse model of Kabuki syndrome. Mol Ther Methods Clin Dev. 2021;20:779-791. Published 2021 Feb 18